Search

Your search keyword '"Karuna, Shelly"' showing total 5 results
Start Over Author "Karuna, Shelly" Journal plos one
5 results on '"Karuna, Shelly"'

2. Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120

Author

deCamp, Allan C., primary, Rolland, Morgane, additional, Edlefsen, Paul T., additional, Sanders-Buell, Eric, additional, Hall, Breana, additional, Magaret, Craig A., additional, Fiore-Gartland, Andrew J., additional, Juraska, Michal, additional, Carpp, Lindsay N., additional, Karuna, Shelly T., additional, Bose, Meera, additional, LePore, Steven, additional, Miller, Shana, additional, O'Sullivan, Annemarie, additional, Poltavee, Kultida, additional, Bai, Hongjun, additional, Dommaraju, Kalpana, additional, Zhao, Hong, additional, Wong, Kim, additional, Chen, Lennie, additional, Ahmed, Hasan, additional, Goodman, Derrick, additional, Tay, Matthew Z., additional, Gottardo, Raphael, additional, Koup, Richard A., additional, Bailer, Robert, additional, Mascola, John R., additional, Graham, Barney S., additional, Roederer, Mario, additional, O’Connell, Robert J., additional, Michael, Nelson L., additional, Robb, Merlin L., additional, Adams, Elizabeth, additional, D’Souza, Patricia, additional, Kublin, James, additional, Corey, Lawrence, additional, Geraghty, Daniel E., additional, Frahm, Nicole, additional, Tomaras, Georgia D., additional, McElrath, M. Juliana, additional, Frenkel, Lisa, additional, Styrchak, Sheila, additional, Tovanabutra, Sodsai, additional, Sobieszczyk, Magdalena E., additional, Hammer, Scott M., additional, Kim, Jerome H., additional, Mullins, James I., additional, and Gilbert, Peter B., additional

Published
2017
Full Text
View/download PDF

3. Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants

Author

Churchyard, Gavin, primary, Mlisana, Koleka, additional, Karuna, Shelly, additional, Williamson, Anna-Lise, additional, Williamson, Carolyn, additional, Morris, Lynn, additional, Tomaras, Georgia D., additional, De Rosa, Stephen C., additional, Gilbert, Peter B., additional, Gu, Niya, additional, Yu, Chenchen, additional, Mkhize, Nonhlanhla N., additional, Hermanus, Tandile, additional, Allen, Mary, additional, Pensiero, Michael, additional, Barnett, Susan W., additional, Gray, Glenda, additional, Bekker, Linda-Gail, additional, Montefiori, David C., additional, Kublin, James, additional, and Corey, Lawrence, additional

Published
2016
Full Text
View/download PDF

5. Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection.

Author

Lama, Javier R., Karuna, Shelly T., Grant, Shannon P., Swann, Edith M., Ganoza, Carmela, Segura, Patricia, Montano, Silvia M., Lacherre, Martin, De Rosa, Stephen C., Buchbinder, Susan, Sanchez, Jorge, McElrath, M. Juliana, Lemos, Maria P., and null, null

Subjects
*HIV prevention, *SIGMOIDOSCOPY, *CIRCUMCISION, *AIDS vaccines, *DRUG design, *COHORT analysis
Abstract

Background: Rectal and genital sampling in HIV prevention trials permits assessments at the site of HIV entry. Yet the safety and acceptability of circumcision and sigmoidoscopy (and associated abstinence recommendations) are unknown in uncircumcised men who have sex with men (MSM) at high risk of HIV infection. Methods: Twenty-nine HIV-seronegative high-risk Peruvian MSM agreed to elective sigmoidoscopy biopsy collections (weeks 2 and 27) and circumcision (week 4) in a 28-week cohort study designed to mimic an HIV vaccine study mucosal collection protocol. We monitored adherence to abstinence recommendations, procedure-related complications, HIV infections, peripheral immune activation, and retention. Results: Twenty-three (79.3%) underwent a first sigmoidoscopy, 21 (72.4%) were circumcised, and 16 (55.2%) completed a second sigmoidoscopy during the study period. All who underwent procedures completed the associated follow-up safety visits. Those completing the procedures reported they were well tolerated, and complication rates were similar to those reported in the literature. Immune activation was detected during the healing period (1 week post-sigmoidoscopy, 6 weeks post-circumcision), including increases in CCR5+CD4+T cells and α4β7+CD4+T cells. Most participants adhered to post-circumcision abstinence recommendations whereas reduced adherence occurred post-sigmoidoscopy. Conclusion: Rectosigmoid mucosal and genital tissue collections were safe in high-risk MSM. Although the clinical implications of the post-procedure increase in peripheral immune activation markers are unknown, they reinforce the need to provide ongoing risk reduction counseling and support for post-procedure abstinence recommendations. Future HIV vaccine studies should also consider the effects of mucosal and tissue collections on peripheral blood endpoints in trial design and analysis. Trial Registration: ClinicalTrials.gov [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results